Roche

News

Celltrion/Teva's Herceptin biosimilar approved in US

The FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US.

News

Gilead hires Roche's pharma chief Daniel O'Day as CEO

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced.

News

AZ's cancer drug fails again, Roche's rival gets new use

AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication

News

UCB, Roche, and IQVIA take lead in UK life sciences investme...

Pharma giant UCB is to invest around £1 billion in the UK as part of a second life sciences sector deal with the UK government, with industry names such as Roche and IQVIA also committing t

News

Genentech buys NASH biotech Jecure

Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH.

News

'Generation Z' happy to be diagnosed by chatbots

A survey involving young people from ‘Generation Z’ has revealed they want to see the NHS introduce digital solutions to help manage their care, with nearly two thirds saying they would be

Celltrion/Teva's Herceptin biosimilar approved in US

Gilead hires Roche's pharma chief Daniel O'Day as CEO

AZ's cancer drug fails again, Roche's rival gets new use

UCB, Roche, and IQVIA take lead in UK life sciences investme...

Genentech buys NASH biotech Jecure

'Generation Z' happy to be diagnosed by chatbots

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Roche

Editor's Picks